研究者詳細 - 田中　寿志

論文 - 田中　寿志

分割表示 >> ／全件表示85 件中 1 - 85 件目

Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancer.

Morinaga D, Hashimoto K, Asahina H, Tanaka H, Honjo O, Harada T, Yokouchi H, Kikuchi H, Shigaki R, Takashina T, Nakamura K, Kawai Y, Takahashi M, Kida R, Sukoh N, Ito K, Takahashi A, Hommura H, Ohhara Y, Furuta M, Konno S, Hosomi Y, Oizumi S.

Respir Investig. 17 ( 63 ) 373 - 382 2025年03月

Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.

Kinoshita F, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Yamaguchi M, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Yamamoto K, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.

Ther Adv Med Oncol. 2025年03月

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.

Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K.

Lung Cancer 2025年03月

Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.

Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Kinoshita F, Fujishita T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Ishikawa N, Kozuki T, Kawamura T, Saito G, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Nishii K, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.

Ther Adv Med Oncol. 2025年02月

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.

Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H.

Lung Cancer. 2025年01月

Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.

Fujimoto D, Shibaki R, Kimura K, Haratani K, Tamiya M, Kijima T, Sato Y, Hata A, Yokoyama T, Taniguchi Y, Uchida J, Tanaka H, Furuya N, Miura S, Onishi MI, Sakata S, Miyauchi E, Yamamoto N, Koh Y, Akamatsu H.

Lung Cancer. 2025年01月

Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Miura K, Shukuya T, Furuya N, Morita R, Kisohara A, Mouri A, Watanabe S, Tanaka H, Hirata A, Hakozaki T, Hamai K, Matsumoto N, Watanabe K, Ashinuma H, Miyauchi E, Sugano K, Hosokawa S, Amano K, Morita S, Kobayashi K, Maemonodo M, Takahashi K.

J Cachexia Sarcopenia Muscle. 2024年12月

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.

Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M.

Eur J Cancer. 2024年12月

Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).

Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T, Iwashima A, Sugisaka J, Miura Y, Tanaka H, Miyawaki T, Yokouchi H, Miura K, Saito R, Saito G, Kamoshida T, Uchinami Y, Kato T, Kobayashi K, Asahina H.

Cancer Sci. 2024年11月

Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.

Tabe C, Fujita T, Taima K, Tanaka H, Makiguchi T, Itoga M, Ishioka Y, Tasaka S, Fujii H.

Lung Cancer. 197 2024年11月

Non-small cell lung cancer with synchronous brain metastases: Identification of prognostic factors in a retrospective multicenter study (HOT 1701).

Ohhara Y, Kojima T, Honjo O, Yamada N, Sato T, Takahashi H, Takamura K, Takashina T, Sukoh N, Tanaka H, Kawai Y, Fujita Y, Yokoo K, Hommura F, Harada T, Honda R, Amano T, Dosaka-Akita H, Oizumi S, Kinoshita I.

Neurooncol Adv. 2024年10月

Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.

Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H.

Cancer Med. 13 ( 14 ) 2024年07月

Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.

Ishidoya M, Makiguchi T, Tanaka H, Miura T, Nunomura Y, Miura D, Morimoto T, Hasegawa Y, Taima K, Tasaka S

Lung cancer (Amsterdam, Netherlands) 192 107790 2024年06月

Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).

Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S.

Cancer Sci. 115 ( 4 ) 1273 - 1282 2024年04月

Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.

Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H, Yamamoto N, Koh Y, Akamatsu H.

J Immunother Cancer 2024年02月

Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.

J Immunother Cancer. 2024年02月

Role of G-protein-coupled estrogen receptor in the pathogenesis of chronic asthma.

Itoga M, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Saito N, Tomita H, Tasaka S.

Immunol Lett 2024年02月

Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)

Cancer Sci. 2024年01月

Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study).

Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, Nagai Y, Nakagawa T, Igawa S, Harada T, Yoshioka H, Tanaka H, Nogawa H, Satoh H, Shiozawa T, Tsuji K, Kobayashi K, Kaira K.

Thorac Cancer. 2024年01月

A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).

Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.

Eur J Cancer. 2024年01月

A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).

Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.

Eur J Cancer. 2024年01月

Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, Nagai Y, Nakagawa T, Igawa S, Harada T, Yoshioka H, Tanaka H, Nogawa H, Satoh H, Shiozawa T, Tsuji K, Kobayashi K, Kaira K.

Thorac Cancer. 2023年11月

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.

Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.

JTO Clin Res Rep 2023年10月

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).

Hasegawa T, Ariyasu R, Tanaka H, Saito R, Kawashima Y, Horiike A, Sakatani T, Tozuka T, Shiihara J, Saiki M, Tambo, Sonoda T, Miya

Cancer Chemother Pharmacol 2023年07月

Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study.

Takata S, Morikawa K, Tanaka H, Itani H, Ishihara M, Horiuchi K, Kato Y, Ikemura S, Nakagawa H, Nakahara Y, Seki Y, Bessho A, Takahashi N, Hayashi K, Endo T, Takeyama K, Maekura T, Takigawa N, Kawase A, Endoh M, Nemoto K, Kishi K, Soejima K, Okuma Y, Yoshimura K, Saigusa D, Kanai Y, Ueda K, Togashi A, Matsutani N, Seki N.

Ther Adv Med Oncol 2023年06月

Hokkaido Lung Cancer Clinical Study Group Trial. Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.

Morinaga D, Asahina H, Ito S, Honjo O, Tanaka H, Honda R, Yokouchi H, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H

Cancer Med. 2023年05月

Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: A prospective pilot study.

Makiguchi T, Tanaka H, Okudera K, Taima K, Tasaka S.

Transl Lung Cancer Res. 2023年04月

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.

Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.

Intern Med. 62 ( 4 ) 589 - 593 2023年02月

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent.

Nakamura Y, Okumura F, Nihei M, Chubachi K, Sakamoto H, Ishioka Y, Makiguchi T, Tanaka H, Taima K, Yajima N, Kurose A, Tasaka S.

Intern Med. 2023年02月

Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility

Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H.

JAMA Netw Open 6 ( 2 ) 2023年02月

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01)

Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.

Thorac Cancer. 14 ( 2 ) 2023年01月

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.

Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N.

Ther Adv Med Oncol. 14 2022年12月

Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series.

Ishioka Y, Makiguchi T, Itoga M, Tanaka H, Taima K, Goto S, Tasaka S

Chest 162 ( 6 ) e311 - e316 2022年12月

A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630

28 ( 20 ) 4402 - 4409 2022年10月

クライオバイオプシーで診断した肺クリプトコックス症の1例．

小田切遥, 牧口友紀, 福島高志, 石岡佳子, 糸賀正道, 田中寿志, 當麻景章, 田坂定智．

気管支学（日本呼吸器内視鏡学会雑誌) 44 ( 5 ) 325 - 330 2022年09月

Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study.

Fukushima T, Makiguchi T, Tanaka Y, Chubachi K, Ishidoya M, Suzuki S, Tanaka H, Taima K, Hasegawa Y, Okudera K, Tasaka S.

Oncol Lett. 24 ( 4 ) 368 2022年09月

HER2遺伝子変異陽性肺癌に対して化学放射線療法後にデュルバルマブを投与した1例．

佐々木悠子，田中寿志，牧口友紀，小堀由璃，小田切遥，田坂定智．

日本呼吸器学会誌 11(5) 310 - 314 2022年09月

Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia.

Tabe C, Dobashi M, Ishioka Y, Itoga M, Tanaka H, Taima K, Tasaka S.

BMC Res Notes 15 263 2022年07月

Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.

Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S.

2022年06月

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).

Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M.

Thorac Cancer. 2022年05月

Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report.

Makiguchi T, Tanaka H, Taima K, Takayasu S, Tasaka S

Thorac Cancer 13 ( 8 ) 1220 - 1223 2022年04月

Diabetic ketoacidosis shortly after COVID-19 vaccination in a non–small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report

2022年02月

Bilateral Thalamic Lesions Associated With Atezolizumab-Induced Encephalitis: A Follow-up Report With Autopsy Findings.

Nishijima H, Kon T, Seino Y, Yagihashi N, Suzuki C, Nakamura T, Tanaka H, Sakamoto Y, Wakabayashi K, Tomiyama M

Neurology 98 ( 5 ) 204 - 205 2022年02月

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.

Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K

Cancers 14 ( 2 ) 2022年01月

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study

Mimori T, Shukuya T, Ko , Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K

Cancers (Basel) 2022年01月

肺癌診療ガイドライン

田中寿志

肺癌診療ガイドライン2022年度版 2022年

Ⅲ各種抗がん薬　22-17.　MET阻害薬

田中寿志

新臨床腫瘍学（改訂第7版） 2022年

First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).

Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, Kikuchi H, Hommura F, Honda R, Yokoo K, Fujita Y, Oizumi S, Morita R, Ikezawa Y, Tanaka H, Kimura N, Sasaki T, Sukoh N, Takashina T, Harada T, Dosaka-Akita H, Isobe H, Hokkaido Lung Cancer Clinical Study Group Trial.

Scientific reports 11 ( 1 ) 23140 - 23140 2021年11月

Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.

Makiguchi T, Tanaka H, Kamata K, Taima K, Kurose A, Tasaka S

Thoracic cancer 12 ( 20 ) 2811 - 2814 2021年10月

Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.

Makiguchi T, Tanaka H, Kamata K, Taima K, Kurose A, Tasaka S

Thoracic cancer 12 ( 20 ) 2811 - 2814 2021年08月

The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients

2021年07月

The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.

Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S.

JCSM Clin Rep 2021年07月

The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients.

Makiguchi T, Tanaka H, Taima K, Tatsuo S, Iida S, Kakeda S, Tasaka S

JCSM Clinical Reports 6 103 - 108 2021年07月

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N

Thoracic cancer 12 ( 14 ) 2113 - 2121 2021年06月

Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).

Ito S, Asahina H, Honjo O, Tanaka H, Honda R, Oizumi S, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H, Hokkaido Lung Cancer Clinical Study Group Trial.

Lung cancer (Amsterdam, Netherlands) 156 12 - 19 2021年06月

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung.

Masamichi Itoga, Hisashi Tanaka, Kageaki Taima, Yoshiko Ishioka, Hiroaki Sakamoto, Shingo Takanashi, Akira Kurose, Sadatomo Tasaka

BMC research notes 14 ( 1 ) 25 - 25 2021年01月

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.

Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka

Cancer communications (London, England) 41 ( 1 ) 83 - 87 2021年01月

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.

Tanaka H, Taima K, Makiguchi T, Nakagawa J, Niioka T, Tasaka S

Cancer communications (London, England) 41 ( 1 ) 83 - 87 2021年01月

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study.

Dobashi M, Tanaka H, Taima K, Itoga M, Ishioka Y, Shiratori T, Okumura F, Tabe C, Tanaka Y, Morimoto T, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S

SAGE open medicine 9 20503121211023357 - 20503121211023357 2021年

日本臨床　領域別症候群シリーズ　腫瘍性疾患　「Pancoast症候群」

田中　寿志、田坂　定智

肺癌診療ガイドライン　2021年度版 2021年

A Phase I/II study of biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with locally advanced unresectable stage III non-small cell lung cancer.

Tanaka H, Hasegawa Y, Makiguchi T, Okumura F, Tabe C, Shiratori T, Ishioka Y, Itoga M, Taima K, Yokouchi J, Hatayama Y, Aoki M, Tasaka S.

Clin Lung Cancer 22(1) 42 - 48 2021年

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study).

Kei Morikawa, Hisashi Tanaka, Hidetoshi Itani, Saori Takata, Satoshi Watanabe, Kazuma Kishi, Kenzo Soejima, Kyoichi Kaira, Hiroshi Kagamu, Kenichi Yoshimura, Noriyuki Matsutani, Nobuhiko Seki

Therapeutic advances in medical oncology 12 1758835920967254 - 1758835920967254 2020年10月

Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).

Atsushi Nakamura, Hisashi Tanaka, Ryota Saito, Aya Suzuki, Toshiyuki Harada, Sumito Inoue, Toru Yamada, Taku Nakagawa, Daisuke Jingu, Shunichi Sugawara

The oncologist 25 ( 10 ) e1451 - e1456 2020年10月

A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.

Hisashi Tanaka, Yukihiro Hasegawa, Tomonori Makiguchi, Fumihiko Okumura, Chiori Tabe, Toshihiro Shiratori, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Junichi Yokouchi, Yoshiomi Hatayama, Masahiko Aoki, Sadatomo Tasaka

Clinical lung cancer 22 ( 1 ) 42 - 48 2020年10月

A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.

Tanaka H, Hasegawa Y, Makiguchi T, Okumura F, Tabe C, Shiratori T, Ishioka Y, Itoga M, Taima K, Yokouchi J, Hatayama Y, Aoki M, Tasaka S

Clinical lung cancer 22 ( 1 ) 42 - 48 2020年10月

Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.

Toshihiro Shiratori, Hisashi Tanaka, Chiori Tabe, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Shingo Takanashi, Sadatomo Tasaka

Thoracic cancer 11 ( 6 ) 1720 - 1723 2020年06月

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab.

Kageaki Taima, Hisashi Tanaka, Masamichi Itoga, Yoshiko Ishioka, Akira Kurose, Sadatomo Tasaka

Respirology case reports 8 ( 5 ) e00580 - e00580 2020年05月

A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer

Tanaka H, Tabe C, Okumura F, Shiratori T, Ishioka Y, Itoga M, Taima K, Morimoto T, Kimura D, Tsushima T, Tasaka S.

Thorac Cancer 11 1633 - 1638 2020年04月

化学放射線療法後デュルバルマブの投与回避要因（TOPGAN2020-01）

有安亮, 丹保裕一, 谷本梓, 園田智明, 神山潤二, 上浪健, 工藤慶太, 土屋裕子, 西尾誠人, 内堀健, 田中寿志, 宮内栄作, 川嶋庸介, 大柳文義, 堀池篤, 酒谷俊雄, 齊木雅史

肺癌 60 ( 7 ) 966 - 971 2020年

The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.

Hiroaki Sakamoto, Hisashi Tanaka, Toshihiro Shiratori, Keisuke Baba, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka

Molecular and clinical oncology 10 ( 6 ) 610 - 614 2019年06月

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.

Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka, Keisuke Baba, Toshihiro Shiratori, Hiroaki Sakamoto, Junichiro Tsuchiya, Hideyuki Nakagawa, Yukihiro Hasegawa, Hideo Yasugahira, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka

Medical oncology (Northwood, London, England) 36 ( 6 ) 57 - 57 2019年05月

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

Yusuke Okuma, Kei Morikawa, Hisashi Tanaka, Takuma Yokoyama, Hidetoshi Itani, Kazuya Horiuchi, Hideyuki Nakagawa, Nobumasa Takahashi, Akihiro Bessho, Kenzo Soejima, Kazuma Kishi, Akira Togashi, Yae Kanai, Koji Ueda, Katsuhisa Horimoto, Noriyuki Matsutani, Nobuhiko Seki

Thoracic cancer 10 ( 2 ) 395 - 400 2019年02月

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.

Keisuke Baba, Hisashi Tanaka, Hiroaki Sakamoto, Toshihiro Shiratori, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Sadatomo Tasaka

Thoracic cancer 10 ( 2 ) 369 - 372 2019年02月

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.

Baba K, Tanaka H, Sakamoto H, Shiratori T, Tsuchiya J, Ishioka Y, Itoga M, Taima K, Tasaka S

Thorac Cancer 2019年01月

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

Ryo Ko, Takehito Shukuya, Yusuke Okuma, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Akiko Fujiwara, Tomohide Sugiyama, Keisuke Azuma, Keiko Muraki, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Satoshi Morita, Kunihiko Kobayashi, Toshihiro Nukiwa, Kazuhisa Takahashi,

The oncologist 23 ( 10 ) 1210 - 1217 2018年10月

脊髄炎，感覚性軸索型ニューロパチーを呈した傍腫瘍性神経症候群の1例

土屋純一郎，田中　寿志，當麻　景章　他

日本呼吸器学会誌 7 ( 4 ) 212 - 215 2018年07月

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Masamichi Itoga, Yoshiko Ishioka, Hideyuki Nakagawa, Keisuke Baba, Yukihiro Hasegawa, Shingo Takanashi, Sadatomo Tasaka

Medical oncology (Northwood, London, England) 35 ( 3 ) 34 - 34 2018年02月

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.

Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka

BMC cancer 17 ( 1 ) 683 - 683 2017年10月

Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.

Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Kunihiko Nakamura, Yoshihito Tanaka, Masamichi Itoga, Shingo Takanashi, Ken Okumura

BMC research notes 9 ( 1 ) 173 - 173 2016年03月

Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.

Hisashi Tanaka, Atsushi Horiike, Toshio Sakatani, Ryota Saito, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Takeshi Horai, Makoto Nishio

Anti-cancer drugs 26 ( 5 ) 573 - 578 2015年06月

Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus.

Masamichi Itoga, Yuko Asari, Takeshi Morimoto, Kageaki Taima, Kunihiko Nakamura, Yoshihito Tanaka, Hisashi Tanaka, Shingo Takanashi, Hiroyuki Kayaba, Ken Okumura

BMC research notes 8 268 - 268 2015年06月

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Atsushi Horiike, Nobuyuki Yamamoto, Hisashi Tanaka, Noriko Yanagitani, Keita Kudo, Fumiyoshi Ohyanagi, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takeshi Horai, Makoto Nishio

Anticancer research 34 ( 4 ) 1975 - 1981 2014年04月

The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review.

Hisashi Tanaka, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Kunihiko Nakamura, Akihito Hayashi, Akira Kurose, Ken Okumura, Shingo Takanashi

OncoTargets and therapy 7 87 - 90 2013年12月

Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma.

Hisashi Tanaka, Kiyoshi Tone, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Hideyuki Nakagawa, Shingo Takanashi, Ken Okumura, Akira Kurose

Lung cancer (Amsterdam, Netherlands) 80 ( 3 ) 289 - 292 2013年06月

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Hisashi Tanaka, Akihito Hayashi, Takeshi Morimoto, Kageaki Taima, Yoshihito Tanaka, Michiko Shimada, Akira Kurose, Shingo Takanashi, Ken Okumura

BMC cancer 12 558 - 558 2012年11月

　前のページ-次のページ　

<田中 寿志>

論文 - 田中 寿志

<田中　寿志>

論文 - 田中　寿志